This Phase I trial is now open at Middlemore Hospital in Auckland for t (11,14 ) RRMM patients.
They will get a new oral agent – a BCL2 like drug.
They will accept referrals from haematologists only from
Other DHB’s.
Contact. Rajeev.Rajagopal@middlemore.co.nz